Bifurcation Lesions, Drug Eluting Balloon
Conditions
Keywords
Bifurcation Lesions, drug eluting balloon, paclitaxel, drug coated balloon
Brief summary
The purpose is to observe and evaluate the safety and efficacy of Bingo drug-eluting balloon in the treatment of patients with bifurcation lesions of coronary artery.
Interventions
DEVICEDrug-eluting balloon
Treat the side branch of bifurcation lesion with drug-eluting balloon
DEVICEUncoated ballloon
Treat the side branch of bifurcation lesion with uncoated balloon
Sponsors
Yinyi(Liaoning) Biotech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or non-pregnant female ages 18-80 years old 2. Patients with asymptomatic myocardial ischemia symptom, stable or unstable angina pectoris or old myocardial infarction 3. Patients with bifurcation lesions of coronary artery observed by angiography. 4. The main branch of the vessels are suitable for PCI and stent therapy, and the side branch are intended to implement the kissing dilatation without considering dual stent implantation. 5. De Novo bifurcation lesions and diameter stenosis are not less than70%; 6. Referenced vessel diameters range from 1.25mm to 5.0mm, and lesions range are not more than 40mm 7. Residual stenosis are not more than 50% after predilatation; 8. Patients who understand the purpose of this trial, voluntary and sign informed consent.
Exclusion criteria
1. Heavily calcified lesions which cannot be dalatated successfully, and the lesions which are not suitable by balloon angioplasty 2. Left main coronary artery lesions without protection or related bifurcation lesions 3. Patients with severe heart failure symptoms (above NYHA III) or Left ventricular ejection fraction (LVEF) below 35% (ultrasound or left ventricular angiography) 4. Impairment of the renal function preoperative: Serum creatinine above 2.0mg/dl； 5. Patients with hemorrhagic tendency, the history of active digestive ulcers, the history of subarachnoid hemorrhage cerebral hemorrhage, antiplatelet and anticoagulant therapy contraindication and unable to anticoagulant therapy; 6. Patients who are allergic to aspirin, ticagrelor, clopidogrel, ticlopidine, heparin, contrast agent and paclitaxel, and cannot 1-year tolerate dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor) 7. Patients whose expected lives are less than 1 year; 8. Patients who are considered to have poor compliance and cannot complete the trial in accordance with requirements. 9. In-stent restenosis lesions 10. Patients who are enrolled in this trial and need stent therapy due to vascular laceration or severe stenosis, and those patients are calculated as fall off cases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target lesion Stenosis (diameter, %) | 9 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thrombosis | 1, 6 and 9 months | — |
| TLR | 1, 6 and 9 months | — |
| TVR | 1, 6 and 9 months | — |
| Non-fatal MI, thrombosis | 1, 6 and 9 months | — |
| MACCE | 1, 6 and 9 months | all-cause death, MI, stroke and TVR |
| All-cause death | 1, 6 and 9 months | — |
| Cardiac death | 1, 6 and 9 months | — |
| TLF | 1, 6 and 9 months | cardiac death, target vessel MI, TLR |
Countries
China
Outcome results
None listed